Clinical trial
A Clinical Trial to Compare Efficacy and Tolerability of Faslodex With Arimidex…
NCT00274469 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00274469 |
|---|---|
| Title | A Clinical Trial to Compare Efficacy and Tolerability of Faslodex With Arimidex in Patients With Advanced Breast Cancer |
| Official title | A Randomized, Open-Label, Parallel-Group, Multicentre, Phase II Study to Compare the Efficacy and Tolerability of Fulvestrant (FASLODEX™) 500 mg With Anastrozole (ARIMIDEX™) 1 mg as First Line Hormonal Treatment for Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer |
| Acronym | FIRST |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Metastatic Breast Cancer |
| Intervention type | Drug |
| Interventions | fulvestrant, anastrozole |
| Enrollment | 205 |
| Start date | Feb 6, 2006 |
| Primary completion | Jan 10, 2008 |
| Completion | Jan 13, 2017 |
| First posted | Jan 11, 2006 |
| Last update posted | Sep 6, 2019 |
| Countries | Brazil, Bulgaria, Czechia, France, Italy, Poland, Spain, United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: